Sinotherapeutics (SH:688247) Zheng Quan Ri Bao·2025-10-30 23:13Core Viewpoint - The company, Shanghai Xuantai Pharmaceutical Co., Ltd., has reported significant developments in its product approvals and market strategies, which are expected to enhance its competitive position and market share in both domestic and international markets [7][9]. Financial Data - The financial statements for the third quarter are unaudited, and the report period covers three months from the beginning to the end of the quarter [3][9]. - The company has not reported any non-recurring gains or losses that are significant enough to be classified differently from regular financial metrics [4][9]. Shareholder Information - As of the end of the reporting period, the company holds 4,336,109 shares in its repurchase account, representing 0.96% of the total share capital [5]. Product Approvals and Market Expansion - The company received approval from the National Medical Products Administration (NMPA) for a new specification of its product, Sitagliptin Metformin Sustained-Release Tablets 50/500mg, which is expected to better meet patient needs and enhance market competitiveness [7]. - The product, Tocilizumab Sustained-Release Tablets 11mg, has received formal approval from the U.S. Food and Drug Administration (FDA), while Sitagliptin Metformin Sustained-Release Tablets have received temporary approval from the FDA, indicating potential for expanded sales in the U.S. market [7]. - The company’s product, Olaparib Tablets, is set to be included in the 11th batch of national centralized drug procurement, which could lead to increased sales and market share if procurement contracts are signed and executed [7].